Global exponential synchronization of memristor-based recurrent neural networks with time-varying delays

This paper deals with the problem of global exponential synchronization of a class of memristor-based recurrent neural networks with time-varying delays based on the fuzzy theory and Lyapunov method. First, a memristor-based recurrent neural network is designed. Then, considering the state-dependent properties of the memristor, a new fuzzy model employing parallel distributed compensation (PDC) gives a new way to analyze the complicated memristor-based neural networks with only two subsystems. Comparisons between results in this paper and in the previous ones have been made. They show that the results in this paper improve and generalized the results derived in the previous literature. An example is also given to illustrate the effectiveness of the results.     

DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果

目的 探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)联合表皮生长因子受体酪氨酸激酶抑制剂(EGRF-TKI)治疗老年晚期表皮生长因子受体(EGFR)突变肺癌的临床疗效。 方法 将70例Ⅳ期EGFR突变肺癌患者分为治疗组和对照组。治疗组35例,给予DC-CIK细胞治疗联合吉非替尼或厄洛替尼靶向治疗;对照组35例,给予吉非替尼或厄洛替尼靶向治疗。 结果 治疗组的疾病控制率(DCR)为88.6%,高于对照组的68.6%(P=0.041),治疗组生活质量评分改善率为71.4%,高于对照组的45.7%(P=0.029),差异均有统计学意义。治疗组和对照组的1年、2年和3年总生存(OS)率分别为62.9% vs 57.1%、37.1% vs 31.4%和8.6% vs 2.9%,两组比较差异无统计学意义(P=0.217)。治疗组和对照组的1年、2年和3年无进展生存(PFS)率分别为57.1% vs 31.4%、20.0% vs 5.7%和2.9% vs 0%,两组差异有统计学意义(P=0.005)。多因素分析显示,腺癌(HR=0.178,95%CI:0.061~0.523)及高分化(HR=0.058,95%CI:0.015~0.228)患者OS更长,腺癌(HR=0.271,95%CI:0.094~0.777)及高分化(HR=0.089,95%CI:0.029~0.272)患者PFS也更长。治疗组和对照组不良反应发生率差异无统计学意义(P>0.05)。 结论 DC-CIK细胞联合EGRF-TKI可以提高晚期老年EGFR突变肺癌患者的疾病控制率和生活质量,延长患者的PFS。     

不同剂量右美托咪啶对小儿七氟烷麻醉术后急性躁动及睁眼时间的影响

目的：探讨右美托咪啶用于减轻小儿七氟烷麻醉术后急性躁动的有效剂量。方法将105例ASAⅠ～Ⅱ级行手术的患儿采用数字表法随机分为三组,每组35例,患儿吸入3％七氟烷进行麻醉诱导,对照组患儿静脉注射0．9％氯化钠注射液2 mL,观察1组患儿注射右美托咪啶0．15μg/kg,观察2组患儿注射右旋美托咪啶0．30μg/kg,然后放置口咽通气道辅助通气,行骶管阻滞。麻醉维持使用1．2％七氟烷,维持其自主通气。记录患儿血流动力学和呼吸的改变。在麻醉结束时记录睁眼的时间（ TEO ）。结果对照组、观察1组、观察2组TEO分别为（8．45±4．02）min、（9．23±5．03）min、（10．81±4．06）min,差异均无统计学意义（均P＞0．05）。观察1组的躁动发生率（20．00％）显著低于对照组（42．86％）（χ^2＝31．42,P＜0．05）,观察2组（8．57％）显著低于对照组和观察1组（χ^2＝24．37、7．53,均P＜0．05）。结论右美托咪啶可有效预防小儿七氟烷麻醉术后急性躁动,0．30μg/kg剂量既有效又安全。     

血管外肺水、肿瘤坏死因子-α、E-选择素、血管抑制因子-2与急性呼吸窘迫综合征患者预后的相关性研究

目的：分析血管外肺水（ EVLW）、肿瘤坏死因子-α（ TNF-α）、E-选择素、血管抑制因子-2与急性呼吸窘迫综合征（ ARDS）的相关性,探讨EVLW、TNF-α、E-选择素、血管抑制因子-2在ARDS病情严重程度及预后判断中的参考价值。方法选择36例ARDS患者进行PiCCO监测,根据PiCCO监测指标血管外肺水指数（ EVLWI）的高低分为两组,EVLWI≥14 mL/kg组和EVLWI＜14 mL/kg组,监测记录患者EVLWI、PVPI、CI、ITBVI等血流动力学指标,观察患者血气分析结果,记录氧合指数、计算APACHEⅡ评分,应用ELISA方法检测两组患者血清TNF-α、E-选择素、血管抑制因子-2水平。结果 EVLWI≥14 mL/kg组患者APACHEⅡ评分为（23．93±4．44）分、28 d病死率为61．1％、ICU住院时间为（19．05±4．0） d,均较 EVLWI ＜14 mL/kg组[APACHEⅡ评分为（18．58±3．66）分、28 d病死率为27．8％、ICU住院时间为（14．35±3．39）d]高（t＝3．941,χ2＝4．050,t＝3．797,均P＜0．01）;同时血清TNF-α为（85．28±18．25）μg/L、E-选择素为（74．07±14．57）μg/L,也较EVLWI＜14 mL/kg组[TNF-α为（63．27±20．28）μg/L、E-选择素为（40．99±16．35）μg/L]高（t＝3．422、5．847,均P＜0．01）;EVLWI≥14 mL/kg组氧合指数为（122．86±25．45）,较EVLWI＜14 mL/kg组的（156．77±37．58）低（t＝-3．170,P＜0．01）。两组中28 d内仍存活的20例患者（存活组）,在入组后经72 h积极治疗后EVLWI明显下降（Z＝-0．392,P＜0．01）,氧合指数较前升高（Z＝-3．845,P＜0．01）,且TNF-α、E-选择素水平均较前下降（t＝7．194、4．025,均P＜0．01）;而死亡组16例患者经72 h积极治疗后EVLWI、TNF-α、E-选择素水平较前无下降,氧合指数较前无改善,差异无统计学意义（均P＞0．05）。 EVLWI 与PVPI、EVLWI 与TNF-α、EVLWI与E-选择素均呈显著正相关（r＝0．605、0．649、0．549,均P＜0．01）?     

盐酸莫西沙星氯化钠注射液无菌检查方法的建立

目的建立盐酸莫西沙星氯化钠注射液无菌检查方法。方法参照《中国药典》2010年版方法进行试验。结果采用薄膜过滤法（冲洗量：400ml／膜）并结合中和法（每100ml培养基加入：0．1mol／L的硫酸锰溶液5ml）即可消除样品对各菌株的抗菌活性。结论建立的方法可行,可用于盐酸莫西沙星氯化钠注射液无菌检查。     

低分子肝素在心脏机械瓣膜置换术后早期过渡抗凝治疗中的应用

心脏机械瓣膜置换术后由于异物的置入,激活了内源性及外源性凝血机制,容易在人造瓣膜周围形成血栓,临床上常规使用华法林抗凝治疗。但在术后早期（〈1个月,尤其是术后0～5天）由于华法林抗凝起效慢,更易形成血栓。有观点认为,术后在华法林起效前,加用低分子肝素联合华法林治疗对确保远期疗效具有重要的意义。但另有观点认为,在术后早期由于体外循环、心脏手术的影响,患者凝血、抗凝、纤溶及血小板等系统尚不稳定,患者处于低凝状态,加用低分子肝素过渡抗凝会增加患者出血的风险。本文总结国内外相关文献,阐述低分子肝素在心脏机械瓣膜置换术后早期过渡抗凝治疗中的应用。     

应用正交试验减少静脉用药集中调配中心难溶性抗菌药物残留量

[摘要]目的：利用正交试验降低静脉用药调配中心难溶抗菌药物的残留量。方法：选定溶媒类型、溶媒体积和溶药针类型三个因素,每个因素确定两个水平,即溶媒类型为0.9%氯化钠注射液和灭菌注射用水,溶媒体积为5 mL和8 mL,溶药针类型为直孔溶药针和侧孔溶药针,进行三因素两水平的正交试验,考察各个因素对静脉用药调配中心难溶抗菌药物残留体积和残留量的影响。结果：影响静脉用药调配中心难溶抗菌药物残留体积的主次因素为溶药针类型最大,溶媒体积次之,溶媒类型最小;影响残留量的主次因素为溶媒体积最大,溶药针类型次之,溶媒类型最小。结论：选择适宜溶媒类型、溶媒体积和溶药针类型调配难溶性抗菌药物,可降低西林瓶内的残留量,提高成品输液质量。     

参芎葡萄糖注射液联合缬沙坦胶囊治疗肾性高血压的效果研究

目的：探讨参芎葡萄糖注射液联合缬沙坦胶囊治疗肾性高血压的临床效果。方法回顾性分析2013年4月～2014年3月我院收治的肾性高血压患者136例,按照就诊的先后顺序分为观察组及对照组,每组68例,对照组单独采用缬沙坦胶囊治疗,观察组采用参芎葡萄糖注射液联合缬沙坦胶囊治疗,比较两组临床总有效率、治疗前后收缩压及舒张压情况、治疗前后肾功能及不良反应发生率。结果（1）观察组临床总有效率与对照组比较明显较高（P＜0.05）。（2）两组治疗后的收缩压、舒张压、BUN及Cr水平与治疗前比较均明显降低,Scr水平明显升高,观察组治疗后各项指标改善的程度与对照组比较更明显（P＜0.05）。（3）两组不良反应发生率差异无统计学意义（P＞0.05）。结论参芎葡萄糖注射液联合缬沙坦治疗肾性高血压疗效确切,安全性高,可以作为一种有效的治疗方式在临床推广应用。     

LC–MS/MS assay for pitavastatin in human plasma and subsequent application to a clinical study in healthy Chinese volunteers

A rapid, selective and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been developed and validated for the determination of pitavastatin in human plasma. Following a liquid–liquid extraction, both the analytes and internal standard telmisartan were separated on a Luna C₁₈ column with a mobile phase consisted of acetonitrile–methanol–1% formic acid in water (50:25:25, v/v/v). Mass spectrometric detection involved electrospray ionization in the positive ion mode followed by multiple reaction monitoring (MRM) of the transitions at m/z 421.9 → 290.1 for pitavastatin and m/z 515.2 → 276.2 for the IS. The assay for pitavastatin showed good linearity (r ≥ 0.99) over the ranges 0.2–400 ng/ml, with a lower limit of quantitation of 0.2 ng/ml. Accuracy and precision for the assay were determined by calculating the intra- and inter-batch variation of quality control (QC) samples at three concentration levels, with relative standard deviations (RSD) of less than 15% for both analytes. The mean extraction recovery of pitavastatin and IS were both above 70%. Matrix effect hasn't been found in this method. The method has been successfully applied to a clinic pharmacokinetic study of pitavastatin administered.     

Investigation on the role of different conductive polymers in supercapacitors based on a zinc sulfide/reduced graphene oxide/conductive polymer ternary composite electrode

Conductive polymers, such as polyaniline (PANI), polypyrrole (PPy), polythiophene (PTh) and poly 3,4-ethylenedioxythiophene (PEDOT), play an important role in the application of pseudocapacitors. It is necessary to explore the effects of different conductive polymers in electrode composites. Herein, we prepare zinc sulfide/reduced graphene oxide (ZnS/RGO) by the hydrothermal method, and conductive polymers (PANI, PPy, PTh and PEDOT) doped with the same mass ratio (polymer to 70 wt%) via in situ polymerization on the surface of ZnS/RGO composite. For the supercapacitor application, the ZnS/RGO/PANI ternary electrode composite possesses the best capacitance performance and cycle stability out of all of the polymer-coated ZnS/RGO composites. In the three-electrode system, the discharge specific capacitance and cycle stability of ZnS/RGO/PANI are 1045.3 F g⁻¹ and 160% at 1 A g⁻¹ after 1000 loops. In a two-electrode symmetric system, the discharge specific capacitance and cycle stability of ZnS/RGO/PANI are 722.0 F g⁻¹ and 76.1% at 1 A g⁻¹ after 1000 loops, and the greatest energy and power density of the ZnS/RGO/PANI electrode are 349.7 W h kg⁻¹ and 18.0 kW kg⁻¹. In addition, conductive polymers can effectively improve the voltage range of the electrode composites in 6 M KOH electrolyte for the two-electrode system. The discharge voltage ∼1.6 V makes them promising electrode materials for supercapacitors.

Conductive polymers, such as polyaniline (PANI), polypyrrole (PPy), polythiophene (PTh) and poly 3,4-ethylenedioxythiophene (PEDOT), play an important role in the application of pseudocapacitors.